[Featured Stock] Cellumed Hits Upper Limit on News of Injectable Skin Graft Development
Bio and medical device company Cellumed is hitting the daily limit after news of developing an injectable skin graft product.
![[Featured Stock] Cellumed Hits Upper Limit on News of Injectable Skin Graft Development](http://www.asiae.co.kr/news/img_view.htm?img=2024072208164559128_1721603806.jpg)
As of 10:29 AM on the 30th, Cellumed is trading at 2,540 KRW, up 29.79% from the previous close.
On this day, Cellumed announced that it has completed the development of the new injectable skin graft product, 'Celluderm Gen,' and plans to begin production facility inspections and prototype development early next year.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Cellumed explained that 'Celluderm Gen' can be applied to simple procedures such as pain relief for degenerative arthritis and joint injections, allowing it to immediately contribute to sales upon commercialization, and its use in the cosmetic field is also on the rise.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
